FDA Advisory Committee Recommends Four Peptides for 503A Compounding List Despite Limited Evidence

The U.S. Food and Drug Administration’s Pharmacy Compounding Advisory Committee (PCAC) has completed its review of seven peptide substances nominated for inclusion on the Section 503A Bulks List, recommending that BPC-157, KPV, TB-500, and MOTS-c be included among the bulk drug substances that may be used by state-licensed traditional compounding pharmacies under Section 503A of the Federal Food, Drug, and Cosmetic Act.

During the two-day meeting, FDA reviewers recommended against several of the nominations, citing limited clinical evidence supporting their safety and effectiveness. However, a majority of committee members concluded that the available information supported recommending the four peptides for inclusion under the statutory criteria governing the 503A Bulks List.

The discussions highlighted the growing demand for peptide-based therapies, many of which, according to comments made during the meeting, are already being obtained through unregulated online sources despite lacking FDA-approved drug products. Committee members weighed whether allowing licensed compounding pharmacies to prepare these peptides under regulatory oversight could improve product quality, enhance patient safety, and address unmet clinical needs while maintaining appropriate regulatory safeguards.

Committee recommends four peptide nominations despite limited clinical evidence

On the first day of the meeting, the committee reviewed BPC-157, KPV, TB-500, and MOTS-c, which have been nominated for compounding for proposed uses including wound healing, inflammatory disorders, metabolic conditions, and osteoporosis.

FDA reviewers emphasized that the available evidence consisted primarily of limited clinical and nonclinical data and did not adequately establish the safety or effectiveness of the nominated peptides for use in compounded medications. FDA staff therefore recommended against adding these substances to the 503A Bulks List.

Despite these concerns, the committee voted to recommend all four peptides for inclusion. The vote on TB-500 was the closest, with eight members voting in favor, six opposed, and one abstaining. Several committee members noted that patients are already obtaining peptide products from unregulated online vendors and argued that permitting compounding through licensed pharmacies could provide greater quality oversight and reduce potential safety risks compared with products obtained from unregulated sources.

Second day focused on three additional peptide nominations

On July 24, the committee evaluated emideltide (DSIP), Semax, and Epitalon, which have been nominated for proposed uses including opioid withdrawal, chronic insomnia, narcolepsy, cerebral ischemia, migraine, and trigeminal neuralgia.

FDA reviewers again concluded that the available evidence did not sufficiently demonstrate the safety and effectiveness of these substances and maintained that broader access should be supported by stronger clinical evidence.

The committee ultimately voted against recommending emideltide (DSIP) for inclusion on the 503A Bulks List, with seven members voting against, six supporting the recommendation, and one abstaining.

The committee also discussed Semax and Epitalon, with members weighing the limited clinical evidence against patient demand and the potential public health benefit of allowing regulated pharmacy compounding rather than continued reliance on unregulated products. Throughout the meeting, committee members repeatedly debated how to balance patient access with the need for robust scientific evidence supporting compounded peptide therapies.

How FDA evaluates substances for the 503A Bulks List

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA evaluates nominated bulk drug substances using several statutory and regulatory considerations, including the clinical need for compounding, available safety information, historical use in pharmacy compounding, and the potential risks associated with permitting or denying their use in compounded medications.

The Pharmacy Compounding Advisory Committee reviews the available scientific evidence and provides independent recommendations to FDA. However, the committee serves solely in an advisory capacity, and its recommendations are non-binding.

What inclusion on the 503A Bulks List means

The 503A Bulks List identifies bulk drug substances that may be used by state-licensed compounding pharmacies to prepare customized medications for individually identified patients pursuant to valid prescriptions.

Compounded drugs prepared under Section 503A are exempt from certain FDA requirements, including premarket approval, provided they satisfy all applicable statutory conditions.

Inclusion of a substance on the 503A Bulks List does not constitute FDA approval of a drug product and does not establish that the substance is safe or effective. Instead, it permits qualified compounding pharmacies to use the substance when all applicable requirements of Section 503A are met.

In addition to the committee’s recommendations, FDA considers the available scientific evidence, public comments, historical compounding practices, and broader public health implications before reaching a final regulatory decision.

FDA will make the final regulatory determination

Although the committee’s recommendations represent an important milestone in the review process, the FDA is not required to adopt the panel’s advice. The agency will independently evaluate the committee’s recommendations alongside the scientific evidence, stakeholder input, and other regulatory considerations before determining whether any of the nominated peptide substances should be added to the 503A Bulks List through its regulatory process.

If the FDA ultimately adopts the committee’s recommendations, licensed compounding pharmacies would be permitted to compound the recommended peptide substances under Section 503A, potentially expanding patient access through regulated pharmacy channels. At the same time, the decision is expected to influence the rapidly evolving peptide compounding market while continuing to fuel debate over the level of clinical evidence necessary to support broader access to compounded peptide therapies.

Reference

U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee Meeting, July 23–24, 2026.